1. Home
  2. SPFI vs CRVS Comparison

SPFI vs CRVS Comparison

Compare SPFI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo South Plains Financial Inc.

SPFI

South Plains Financial Inc.

HOLD

Current Price

$43.68

Market Cap

820.1M

Sector

Finance

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

SELL

Current Price

$10.23

Market Cap

811.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SPFI
CRVS
Founded
1941
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
820.1M
811.8M
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
SPFI
CRVS
Price
$43.68
$10.23
Analyst Decision
Buy
Strong Buy
Analyst Count
4
8
Target Price
★ $50.50
$33.14
AVG Volume (30 Days)
80.1K
★ 1.0M
Earning Date
10-22-2026
11-03-2026
Dividend Yield
★ 1.65%
N/A
EPS Growth
17.81
★ 48.04
EPS
★ 1.82
N/A
Revenue
N/A
N/A
Revenue This Year
$17.77
N/A
Revenue Next Year
$8.74
N/A
P/E Ratio
$24.05
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$35.34
$6.39
52 Week High
$46.94
$26.95

Technical Indicators

Market Signals
Indicator
SPFI
CRVS
Relative Strength Index (RSI) 51.33 39.79
Support Level $42.76 $9.21
Resistance Level $44.13 $13.73
Average True Range (ATR) 0.85 0.56
MACD 0.16 0.07
Stochastic Oscillator 61.31 50.65

Price Performance

Historical Comparison
SPFI
CRVS

About SPFI South Plains Financial Inc.

South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: